The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
IL-1 is required for tumor invasiveness and angiogenesis
Open accessAbstract
Here, we describe that microenvironmental IL-1β and, to a lesser extent, IL-1α are required for in vivo angiogenesis and invasiveness of different tumor cells. In IL-1β knockout (KO) mice, local tumor or lung metastases of B16 melanoma cells were not observed compared with WT mice. Angiogenesis was assessed by the recruitment of blood vessel networks into Matrigel plugs containing B16 melanoma cells; vascularization of the plugs was present in WT mice, but was absent in IL-1β KO mice. The addition of exogenous IL-1 into B16-containing Matrigel plugs in IL-1β KO mice partially restored the angiogenic response. Moreover, the incorporation of IL-1 receptor antagonist to B16-containing plugs in WT mice inhibited the ingrowth of blood vessel networks into Matrigel plugs. In IL-1α KO mice, local tumor development and induction of an angiogenic response in Matrigel plugs was less pronounced than in WT mice, but significantly higher than in IL-1β KO mice. These effects of host-derived IL-1α and IL-1β were not restricted to the melanoma model, but were also observed in DA/3 mammary and prostate cancer cell models. In addition to the in vivo findings, IL-1 contributed to the production of vascular endothelial cell growth factor and tumor necrosis factor in cocultures of peritoneal macrophages and tumor cells. Host-derived IL-1 seems to control tumor angiogenesis and invasiveness. Furthermore, the anti-angiogenic effects of IL-1 receptor antagonist, shown here, suggest a possible therapeutic role in cancer, in addition to its current use in rheumatoid arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Self-citationO'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
Onuegbu, A. J., Olisekodiaka, J. M., Udo, J. U., Umeononihu, O., Amah, U. K., Okwara, J. E., & Atuegbu, C. (2015) · Medical Principles and Practice · doi:10.1159/000381778 · Cited by 2,044
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Blood Vessel Formation: What Is Its Molecular Basis?
Folkman, J., & D'Amore, P. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81810-3 · Cited by 1,215
Matrix metalloproteinases and metastasis
Kleiner, D. E., & Stetler-Stevenson, W. G. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051097 · Cited by 701
Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis
Vlodavsky, I., & Friedmann, Y. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13662 · Cited by 618
Horai, R., Asano, M., Sudo, K., Kanuka, H., Suzuki, M., Nishihara, M., Takahashi, M., & Iwakura, Y. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1463 · Cited by 611
Self-citationHuang, S., Pettaway, C. A., Uehara, H., Bucana, C. D., & Fidler, I. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204535 · Cited by 556
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
Zucker, S., Cao, J., & Chen, W.-T. (2000) · Oncogene · doi:10.1038/sj.onc.1204097 · Cited by 550
Cytokines as communication signals between leukocytes and endothelial cells
Mantovani, A., & Dejana, E. (1989) · Immunology Today · doi:10.1016/0167-5699(89)90270-3 · Cited by 517
Dor, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/21.8.1939 · Cited by 390
Resistance to fever induction and impaired acute-phase response in interleukin-1β-deficient mice
Zheng, H., Fletcher, D., Kozak, W., Jiang, M., Hofmann, K. J., Corn, C. A., Soszynski, D., Grabiec, C., Trumbauer, M. E., Shaw, A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90154-x · Cited by 365
IL-18 regulates IL-1 β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1
Vidal-Vanaclocha, F., Fantuzzi, G., Mendoza, L., Fuentes, A. M., Anasagasti, M. J., Martín, J., Carrascal, T., Walsh, P., Reznikov, L. L., Kim, S.-H., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.734 · Cited by 338
Self-citationSlaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., & Fidler, I. J. (1999) · PubMed · Cited by 337
Factor VIII related antigen as an endothelial cell marker in benign and malignant diseases
Sehested, M., & Hou-Jensen, K. (1981) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00437598 · Cited by 258
Saijo, Y., Tanaka, M., Miki, M., Usui, K., Suzuki, T., Maemondo, M., Hong, X., Tazawa, R., Kikuchi, T., Matsushima, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.469 · Cited by 249
Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts
Thornton, R. D., Lane, P., Borghaei, R. C., Pease, E. A., Jaime, C. A. R. O., & Mochan, E. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3500307 · Cited by 221
Interleukin-1—a major pleiotropic cytokine in tumor–host interactions
Apte, R. N., & Voronov, E. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00014-7 · Cited by 212
Self-citationFridman, R., Kibbey, M. C., Royce, L. S., Zain, M., Sweeney, T. M., Jicha, D. L., Yannelli, J. R., Martin, G. R., & Kleinman, H. K. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.769 · Cited by 206
Effect of endotoxin in IL-1 β-deficient mice
Fantuzzi, G., Zheng, H., Faggioni, R., Benigni, F., Ghezzi, P., Sipe, J. D., Shaw, A. R., & Dinarello, C. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.1.291 · Cited by 190
Self-citationVidal‐Vanaclocha, F., Amezaga, C. A. V.-D., Asumendi, A., Kaplanski, G., & Dinarello, C. A. (1994) · PubMed · Cited by 146
Self-citationAnticancer drug targets: approaching angiogenesis
Keshet, E., & Ben‐Sasson, S. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8849 · Cited by 135
Fu, Y., Watson, G. A., Jimenez, J. J., Wang, Y., & Lopez, D. M. (1990) · PubMed · Cited by 127
Folkman, J. (1990) · Cancer and Metastasis Reviews · doi:10.1007/bf00046358 · Cited by 124
Vidal‐Vanaclocha, F., Alvarez, A., Asumendi, A., Urcelay, B., Tonino, P., & Dinarello, C. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.198 · Cited by 117
Self-citationCoxon, A., Bolon, B. N., Estrada, J., Kaufman, S., Scully, S. A., Rattan, A., Duryea, D., Hu, Y., Rex, K. L., Pacheco, E., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10546 · Cited by 97
Scatena, M., & Giachelli, C. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00151-7 · Cited by 82
Nozaki, S., Sledge, G. W., & Nakshatri, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3241 · Cited by 77
Chirivi, R. G. S., Garofalo, A., Padura, I. M., Mantovani, A., & Giavazzi, R. (1993) · PubMed · Cited by 75
Douvdevani, A., Huleihel, M., Zöller, M., Segal, S., & Apte, R. N. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510526 · Cited by 73
Self-citationAnasagasti, M. J., Alvarez, A., Martin, J. J., Mendoza, L., & Vidal‐Vanaclocha, F. (1997) · Hepatology · doi:10.1002/hep.510250410 · Cited by 54
Voronov, E., Weinstein, Y., Benharroch, D., Cagnano, E., Ofir, R., Dobkin, M., White, R. M., Zöller, M., Barak, V., Segal, S., et al. (1999) · PubMed · Cited by 51
Self-citationChirivi, R. G. S., Chiodoni, C., Musiani, P., Garofalo, A., Bernasconi, S., Colombo, M. P., & Giavazzi, R. (1996) · International Journal of Cancer · Cited by 40
The Contribution of Proangiogenic Factors to the Progression of Malignant Disease
Neufeld, G., Kessler, O., Vadasz, Z., & Gluzman‐Poltorak, Z. (2001) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30069-3 · Cited by 39
Apte, R. N., Douvdevani, A., Zöller, M., White, R. M., Dvorkin, T., Shimoni, N., Fima, E., Hacham, M., Huleihel, M., Benharroch, D., et al. (1993) · Immunology Letters · doi:10.1016/0165-2478(93)90163-v · Cited by 35
Self-citationInterleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo.
McKenzie, R. C., Oran, A. E., Dinarello, C. A., & Sauder, D. N. (1996) · PubMed · Cited by 24
Self-citation
Cited by
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Self-citationTumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Metadata
- Authors
- Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-02-21
- Volume
- 100
- Issue
- 5
- Pages
- 2645-2650
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2050516456
- Cited by
- 1,023
- References
- 47
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.